Filed by Organovo Holdings, Inc.
Pursuant to Rule 425 under the Securities Act of 1933, as amended,
and deemed filed pursuant to Rule 14a-6(b) under
the Securities Act of 1934, as amended
Subject Company: Tarveda Therapeutics, Inc.
File No. of Related Registration Statement: 333-235683
On February 26, 2020, Organovo Holdings, Inc. (Organovo) issued the following press release in connection with the proposed merger pursuant
to the terms of an Agreement and Plan of Merger and Reorganization, dated December 13, 2019 and amended as of January 26, 2020, by and among Organovo, Opal Merger Sub, Inc. and Tarveda Therapeutics, Inc.
Organovo Files Definitive Proxy Statement and Sends Letter to Stockholders
Recommends Stockholders Vote FOR Proposed Merger with Tarveda
SAN DIEGO, Feb. 26, 2020 Organovo Holdings, Inc. (Organovo) (NASDAQ: ONVO) today announced that it has filed definitive proxy
materials with the U.S. Securities and Exchange Commission and has mailed these materials and a letter to its stockholders in connection with the companys Special Meeting to be held on March 26, 2020. Stockholders of record as of
February 14, 2020 will be entitled to vote at the meeting.
Organovo urges its stockholders to vote FOR the proposed merger with Tarveda
Therapeutics, Inc. (Tarveda), the proposed reverse stock split and the other proposals outlined in the definitive proxy statement. After carefully conducting a thorough review of strategic alternatives, the Organovo Board of Directors
and management determined that the proposed merger with Tarveda provides the best path forward for the Organovo stockholders to maximize return on their investment.
The full text of Organovos letter to stockholders is as follows:
Dear Fellow Stockholders,
As most of you are aware, the past
year has been challenging for Organovo. Throughout it all, the Board of Directors and management team have been sharply focused on identifying the best path to maximize value for you, our stockholders. In that spirit, Im reaching out to you
today to encourage you to read the definitive proxy statement/prospectus/information statement that was mailed to you on or around February 26, 2020, and to vote in support of the proposed merger with Tarveda Therapeutics, Inc. and the other
proposals described in the definitive proxy statement/prospectus/information statement which we believe provides the best opportunity to maximize value for our stockholders.